Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Phase 1 Study Of The Novel Kinesin Spindle Protein Inhibitor ARRY-520 + Carfilzomib (Car) In Patients With Relapsed and/Or Refractory Multiple Myeloma (RRMM)

Jatin J. Shah, M.D., Lei Feng, M.S., Sheeba K. Thomas, M.D., Donna M. Weber, M.D., Michael Wang, MD, Brandi Hilder, Raymond Alexanian, M.D., Robert Z. Orlowski, M.D., Ph.D.

Blood (2013) 122 (21): 1982.

https://doi.org/10.1182/blood.V122.21.1982.1982

Published: 2013

Journal Articles

Phase II Study Of The Combination Of MLN 9708 With Lenalidomide As Maintenance Therapy Post Autologous Stem Cell Transplant In Patients With Multiple Myeloma

Jatin J. Shah, M.D., Veera Baladandayuthapani, PhD, Donna M. Weber, M.D., Sheeba K. Thomas, M.D., Raymond Alexanian, M.D., Michael Wang, MD, Muzaffar H. Qazilbash, MD, Richard E Champlin, MD, Nina Shah, MD, Qaiser Bashir, MD, Uday R Popat, MD, Yago Nieto, M.D., Ph.D., Sairah Ahmed, MD, Simrit Parmar, MD, Robert Z. Orlowski, M.D., Ph.D.

Blood (2013) 122 (21): 1983.

https://doi.org/10.1182/blood.V122.21.1983.1983

Published: 2013

Journal Articles

Feasibility and Activity Of Bortezomib-Based Therapy In Patients With Relapsed/Refractory Multiple Myeloma Previously Treated With Carfilzomib

Arti Alagappan, Rupin A Shah, M.B.B.S, Sheeba K. Thomas, M.D., Donna M. Weber, M.D., Michael Wang, MD, Raymond Alexanian, M.D., Robert Z. Orlowski, M.D., Ph.D., Jatin J. Shah, M.D.

Blood (2013) 122 (21): 1994.

https://doi.org/10.1182/blood.V122.21.1994.1994

Published: 2013

Journal Articles

Phase II Study Of The c-MET Inhibitor ARQ 197 (Tivantinib) In Patients With Relapsed Or Relapsed/Refractory Multiple Myeloma (RRMM)

Robert Z. Orlowski, M.D., Ph.D, Shadia Zaman, Ph.D., Sheeba K. Thomas, M.D., Raymond Alexanian, M.D., Jatin J. Shah, M.D., Donna M. Weber, M.D., Michael Wang, MD, Ashley N. Holloway, R.N., Veerabhadran Baladandayuthapani, Ph.D., Heather Yan Lin, Ph.D., Min Fu, Christine M. Stellrecht, Ph.D., Claudia Morales de Partovi, B.S., Varsha Gandhi, PhD

Blood (2013) 122 (21): 1953.

https://doi.org/10.1182/blood.V122.21.1953.1953

Published: 2013

Journal Articles

Circulating Plasma Cells By Routine Complete Blood Count Identify Patients With Similar Outcome As Plasma Cell Leukemia

Rupin A Shah, M.B.B.S, Satyajit Mohite, M.B.B.S., Veerabhadran Baladandayuthapani, Ph.D., Sheeba K. Thomas, M.D., Donna M. Weber, M.D., Michael Wang, MD, Raymond Alexanian, M.D., Muzaffar H Qazilbash, MD, Uday R Popat, MD, Richard E Champlin, MD, Nina Shah, MD, Qaiser Bashir, MD, Simrit Parmar, MD, Yago Nieto, MD, PhD, Sairah Ahmed, MD, Robert Z. Orlowski, M.D., Ph.D., Jatin J. Shah, M.D.

Blood (2013) 122 (21): 5356.

https://doi.org/10.1182/blood.V122.21.5356.5356

Published: 2013

Journal Articles

Final Results of a Phase I/II Trial of the Combination of Concurrent Lenalidomide, Thalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Myeloma

Jatin J. Shah, M.D., Robert Z. Orlowski, M.D., Ph.D., Sheeba K. Thomas, MD, Raymond Alexanian, M.D., Michael Wang, M.D., Muzaffar H. Qazilbash, MD, Uday R. Popat, M.D., Simrit Parmar, M.D., Nina Shah, MD, Qaiser Bashir, Richard E. Champlin, Donna M. Weber, M.D.

Blood (2012) 120 (21): 75.

https://doi.org/10.1182/blood.V120.21.75.75

Published: 2012

Journal Articles

Phase 1/1b Study of the Efficacy and Safety of the Combination of Panobinostat + Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma

Jatin J. Shah, M.D., Sheeba K. Thomas, MD, Donna M. Weber, M.D., Michael Wang, M.D., Raymond Alexanian, M.D., Muzaffar H. Qazilbash, MD, Qaiser Bashir, MD, Simrit Parmar, M.D., Nina Shah, MD, Uday R. Popat, M.D., Robert Z. Orlowski, M.D., Ph.D.

Blood (2012) 120 (21): 4081.

https://doi.org/10.1182/blood.V120.21.4081.4081

Published: 2012

Journal Articles

Phase 1 Study of the Novel Kinesin Spindle Protein Inhibitor ARRY-520 + Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma

Jatin J. Shah, M.D., Donna M. Weber, M.D., Sheeba K. Thomas, MD, Raymond Alexanian, M.D., Michael Wang, M.D., Muzaffar H. Qazilbash, MD, Simrit Parmar, M.D., Nina Shah, MD, Qaiser Bashir, MD, Uday R. Popat, M.D., Brandi Hilder, Robert Z. Orlowski, M.D., Ph.D.

Blood (2012) 120 (21): 4082.

https://doi.org/10.1182/blood.V120.21.4082.4082

Published: 2012

Journal Articles

Phase II Study of the c-Met Inhibitor ARQ 197 (Tivantinib) in Patients with Relapsed Multiple Myeloma.

Stephan Joseph Dorkhom, D.O., Shadia Zaman, Ph.D., Sheeba K. Thomas, MD, Raymond Alexanian, M.D., Jatin J. Shah, M.D., Donna M. Weber, M.D., Michael Wang, M.D., Martha L. Anderson, R.N., Veerabhadran Baladandayuthapani, Ph.D., Yan Heather Lin, Ph.D., Min Fu, Ph.D., Christine M. Stellrecht, Ph.D., Claudia Morales de Partovi, B.S., Varsha V. Gandhi, Ph.D., Robert Z. Orlowski, M.D., Ph.D.

Blood (2012) 120 (21): 2976.

https://doi.org/10.1182/blood.V120.21.2976.2976

Published: 2012

Journal Articles

The Novel KSP Inhibitor ARRY-520 Demonstrates Single-Agent Activity in Refractory Myeloma: Results From a Phase 2 Trial in Patients with Relapsed/Refractory Multiple Myeloma (MM)

Sagar Lonial, MD, Adam Cohen, Jeffrey Zonder, MD, William I Benzinger, MD, Jonathan L. Kaufman, MD, Robert Z. Orlowski, MD, PhD, R. Donald Harvey, PharmD, Raymond Alexanian, M.D., Sheeba K Thomas, M.D., Donna Weber, MD, Duncan Walker, PhD, Brandi Hilder, PhD, Ann Ptaszynski, Jatin J Shah, MD

Blood (2011) 118 (21): 2935.

https://doi.org/10.1182/blood.V118.21.2935.2935

Published: 2011

Journal Articles

ARRY-520 Shows Durable Responses in Patients with Relapsed/Refractory Multiple Myeloma in a Phase 1 Dose-Escalation Study

Jatin J Shah, MD, Jeffrey Zonder, MD, Adam Cohen, Robert Z. Orlowski, MD, PhD, Raymond Alexanian, M.D., Sheeba K Thomas, M.D., Donna Weber, MD, Jonathan L. Kaufman, MD, R. Donald Harvey, PharmD, Duncan Walker, PhD, Kevin Litwiler, PhD, Sharon Karan, Brandi Hilder, Ann Marie Ptaszynski, MD, Sagar Lonial, MD

Blood (2011) 118 (21): 1860.

https://doi.org/10.1182/blood.V118.21.1860.1860

Published: 2011

Journal Articles

Survival Disparities Between African-American and Caucasian Patients with Multiple Myeloma Are Blunted in the Era of Novel Therapeutics and Autologous Stem Cell Transplantation.

Nina Shah, MD, Donna M Weber, M.D., Michael Wang, MD, Sheeba Thomas, MD, Jatin Shah, MD, Sergio Giralt, MD, Raymond Alexanian, M.D., Robert Z Orlowski, M.D., Ph.D., Muzaffar H. Qazilbash, MD, Tiffany Avery, M.D., MPH

Blood (2009) 114 (22): 1395.

https://doi.org/10.1182/blood.V114.22.1395.1395

Published: 2009

Journal Articles

Prognostic Factors for Survival After 2-CdA-Based Therapy for Symptomatic Waldenström Macroglobulinemia (WM) Stratify Patients Into Low- and High-Risk Groups.

Sheeba K Thomas, M.D., Lei Feng, M.S., Kay B Delasalle, B.S., Michael Wang, M.D., Jatin J Shah, M.D., Robert Z Orlowski, M.D., Ph.D., Raymond Alexanian, M.D., Donna M Weber, M.D.

Blood (2009) 114 (22): 1668.

https://doi.org/10.1182/blood.V114.22.1668.1668

Published: 2009

Journal Articles

Curability of Multiple Myeloma.

Kay B Delasalle, BS, Luhua Wang, MD, Donna Weber, MD, Sergio A. Giralt, MD, Sheeba Thomas, MD, Jatin Shah, MD, Beverly Handy, MD, Robert Z. Orlowski, MD, PhD, Raymond Alexanian, M.D.

Blood (2009) 114 (22): 3864.

https://doi.org/10.1182/blood.V114.22.3864.3864

Published: 2009

Journal Articles

Survival Outcomes of Patients Receiving Thalidomide-Dexamethasone for Previously Untreated Multiple Myeloma.

Sheeba K. Thomas, MD, Sergio A. Giralt, M.D., Michael Wang, M.D., Kay B. Delasalle, B.S., Maria Gavino, R.N., Kim Rankin, L.V.N., Raymond Alexanian, M.D., Donna M. Weber, M.D.

Blood (2006) 108 (11): 3569.

https://doi.org/10.1182/blood.V108.11.3569.3569

Published: 2006

Journal Articles

Oxymetholone Treatment for the Anemia of Bone Marrow Failure

Raymond Alexanian, M.D., Judith Nadell, M.D., Clarence Alfrey, M.D.

Blood (1972) 40 (3): 353–365.

https://doi.org/10.1182/blood.V40.3.353.353

Published: 1972

Journal Articles

Melphalan Therapy for Plasma Cell Myeloma

RAYMOND ALEXANIAN, M.D., DANIEL E. BERGSAGEL, M.D., PHILIP J. MIGLIORE, MS., WILLIAM K. VAUGHN, M.D., CLIFTON D. HOWE, M.D.

Blood (1968) 31 (1): 1–10.

https://doi.org/10.1182/blood.V31.1.1.1

Published: 1968

Journal Articles

Urinary Excretion of Erythropoietin in Normal Men and Women

RAYMOND ALEXANIAN, M.D., Brenda Prewitt

Blood (1966) 28 (3): 344–353.

https://doi.org/10.1182/blood.V28.3.344.344

Published: 1966

NARROW

Phase 1 Study Of The Novel Kinesin Spindle Protein Inhibitor ARRY-520 + Carfilzomib (Car) In Patients With Relapsed and/Or Refractory Multiple Myeloma (RRMM)

Phase II Study Of The Combination Of MLN 9708 With Lenalidomide As Maintenance Therapy Post Autologous Stem Cell Transplant In Patients With Multiple Myeloma

Feasibility and Activity Of Bortezomib-Based Therapy In Patients With Relapsed/Refractory Multiple Myeloma Previously Treated With Carfilzomib

Phase II Study Of The c-MET Inhibitor ARQ 197 (Tivantinib) In Patients With Relapsed Or Relapsed/Refractory Multiple Myeloma (RRMM)

Circulating Plasma Cells By Routine Complete Blood Count Identify Patients With Similar Outcome As Plasma Cell Leukemia

Final Results of a Phase I/II Trial of the Combination of Concurrent Lenalidomide, Thalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Myeloma

Phase 1/1b Study of the Efficacy and Safety of the Combination of Panobinostat + Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma

Phase 1 Study of the Novel Kinesin Spindle Protein Inhibitor ARRY-520 + Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma

Phase II Study of the c-Met Inhibitor ARQ 197 (Tivantinib) in Patients with Relapsed Multiple Myeloma.

The Novel KSP Inhibitor ARRY-520 Demonstrates Single-Agent Activity in Refractory Myeloma: Results From a Phase 2 Trial in Patients with Relapsed/Refractory Multiple Myeloma (MM)

ARRY-520 Shows Durable Responses in Patients with Relapsed/Refractory Multiple Myeloma in a Phase 1 Dose-Escalation Study

Survival Disparities Between African-American and Caucasian Patients with Multiple Myeloma Are Blunted in the Era of Novel Therapeutics and Autologous Stem Cell Transplantation.

Prognostic Factors for Survival After 2-CdA-Based Therapy for Symptomatic Waldenström Macroglobulinemia (WM) Stratify Patients Into Low- and High-Risk Groups.

Curability of Multiple Myeloma.

Survival Outcomes of Patients Receiving Thalidomide-Dexamethasone for Previously Untreated Multiple Myeloma.

Oxymetholone Treatment for the Anemia of Bone Marrow Failure

Melphalan Therapy for Plasma Cell Myeloma

Urinary Excretion of Erythropoietin in Normal Men and Women

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only